Special Issue "Inhibitors of Melanogenesis Related Processes: Application to Food, Agricultural and Cosmetic Industry-2014"
Deadline for manuscript submissions: 30 September 2014
Prof. Dr. Manickam Sugumaran
Department of Biology, University of Massachusetts Boston, 100 Morrissey Blvd, Boston, MA 02125, USA
Phone: +1 617 287 6598
Fax: +1 617 287 6650
Interests: enzymology; post translational modifications; aromatic metabolism; phenolic biochemistry; reactions of quinonoid compounds; invertebrate immunity; insect cuticular sclerotization; phenoloxidase; quinone isomerases; oxidative browning; melanin biosynthesis; catecholic antibiotics
Melanogenesis is a pigment-producing process that occurs ubiquitously in all animals, as well as in a wide variety of microorganisms and plants. The enzyme tyrosinase (also known as phenoloxidase) initiates melanogenesis by hydroxylating monophenols to create o-diphenols; these o-diphenols are further oxidized by tyrosinase into o-quinones. The unstable o-quinones undergo rapid transformations that are both nonenzymatic and enzyme catalyzed. Eventually, these transformations create different kinds of polymeric products.
Quinones in general are very reactive and tend to deplete cellular antioxidant pools. They also have deleterious effects on cellular macromolecules. In light of the above, inhibitors of melanogensis have great commercial potential.
For example, oxidative browning reactions reduce the nutritive values of plants. On the other hand, these reactions are advantageous for plants because they help fight off infection and invasion by other organisms. Nevertheless, oxidative browning certainly reduces the market value of food products.
The melanosis observed in crustaceans similarly reduces the market value of seafood drastically. In arthropods and especially insects, melanogenesis is used for wound healing and defense reactions (invertebrate immunity). A parallel process called sclerotization (which is initated through phenoloxidases), ensures the hardening of insect exoskeletons, so as to protect these soft-bodied animals from their environmental enemies. Arrest or even delay of sclerotization has devastating consequences for insects. Consequently, the inhibition of sclerotization provides a valuable tool for fighting noxious insects, and for developing new kinds of insecticides for future use.
Mammals use melanin mostly as skin, coat, and eye pigments. In recent years, dermal melanin production inhibitors have become a valuable tool for the cosmetic industry to produce lighter skin.
Thus, melanogenesis inhibitors have many useful applications. Naturally, lots of research groups have been engaged in discovering novel inhibitors of these enzymes. This Special Issue, which is the second of a series, will cover broad range topics, which include phenoloxidase/tyrosinase chemistry, biochemistry of inhibitors, and methods of either discovering or developing novel bioactive compounds (both natural and synthetic) that inhibit melanogenesis and related processes. This new Special Issue aims to cover the most recent progress made in this area, and will include research papers and authoritative review articles.
Prof. Manickam Sugumaran
You may also be interested in the recent IJMS special issue "Inhibitors of Melanogenesis Related Processes: Application to Food and Cosmetic Industry" (http://www.mdpi.com/journal/ijms/special_issues/melanogenesis_related_processes).
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed Open Access monthly journal published by MDPI.
- phenoloxidase inhibitors
- tyrosinase inhibitors
- inhibitors of melanogenesis
- skin color lightening
- prevention of oxidative browning
- cuticular sclerotization
- invertebrate immunity and melanin
Article: S-(−)-10,11-Dihydroxyfarnesoic Acid Methyl Ester Inhibits Melanin Synthesis in Murine Melanocyte Cells
Int. J. Mol. Sci. 2014, 15(7), 12750-12763; doi:10.3390/ijms150712750
Received: 31 March 2014; in revised form: 1 July 2014 / Accepted: 8 July 2014 / Published: 18 July 2014| PDF Full-text (5097 KB)
Communication: Novel Inhibitory Effect of N-(2-Hydroxycyclohexyl)valiolamine on Melanin Production in a Human Skin Model
Int. J. Mol. Sci. 2014, 15(7), 12188-12195; doi:10.3390/ijms150712188
Received: 30 April 2014; in revised form: 24 June 2014 / Accepted: 26 June 2014 / Published: 9 July 2014| PDF Full-text (1378 KB)
Review: Inhibitors of Intracellular Signaling Pathways that Lead to Stimulated Epidermal Pigmentation: Perspective of Anti-Pigmenting Agents
Int. J. Mol. Sci. 2014, 15(5), 8293-8315; doi:10.3390/ijms15058293
Received: 14 March 2014; in revised form: 17 April 2014 / Accepted: 29 April 2014 / Published: 12 May 2014| PDF Full-text (5096 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Small-Molecule Inhibitors of Receptor Tyrosine Kinases as Emerging Tools for Targeted-based Cancer Cell Therapies
Author: Mohammad Hojjat-Farsangi
Affiliation: Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, Stockholm, Sweden
Abstract: Currently, chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. However, in spite of the improvements in patients life quality, their effectiveness is severely compromised by immune-suppression, changes in the tumor microenvironment and deleterious effects on normal cells. This represents a demand for developing new effective strategies with focusing on tumor cells and minimum side-effects on normal cells. Targeted cellular and molecular therapies or "personalized medicine" have been defined as a new type of emerging treatments. Significant progresses in this field propose the possibilities of replacing current systemic chemotherapies with new emerging therapies. The growing number of approved small-molecule inhibitors (SMI) of receptor tyrosine kinases (RTKs) in the clinical oncology implies on the increasing attention and application of these kinds of therapeutic tools. In this review we overview: (1) the molecular basis and function of SMIs targeting RTKs (2) the recent progresses in the development of SMIs in clinical development and treatment of hematologic malignancies and solid tumors; (3) side effects and complications using SMIs; and (4) future trends of using SMIs in cancer treatment.
Last update: 1 July 2014